# IFM2017_03 (NCT03993912)

> Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03993912
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: University Hospital, Lille
- Conditions: Multiple Myeloma
- Interventions: Daratumumab SC in combination with Lenalidomide; Lenalidomide PO (25mg); Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
- Enrollment: 294
- Primary outcome: Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 21
- YouTube: 14
- Podcasts: 8

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ifm2017-03-nct03993912

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03993912", "email": "<work email>"}; the inbox owner confirms by the emailed link.